Adam Feuerstein
11 stories across 1 outlet
STAT News 14
SpotlightData & AnalysisTechnology & ScienceExplainersBusiness & Finance
Published work
The FDA’s Overton era, and dispatches from Shanghai
STAT News - Spotlight
STAT+: Why Gilead can’t stop talking about its ambitions in immunology
STAT News - Spotlight
Why two promising heart drugs flopped and what’s next
STAT News - Explainers
STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
STAT News - Data & Analysis
STAT+: What to expect from UniQure’s upcoming Huntington’s gene therapy readout
STAT News - Technology & Science
STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
STAT News - Spotlight
STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
STAT News - Spotlight
Definium’s new psychedelics data, and a reprieve for international scientists
STAT News - Technology & Science
STAT+: A Sellas immunotherapy study, long delayed, will end in failure
STAT News - Data & Analysis
STAT+: A biotech hedge fund births a new immunology company
STAT News - Business & Finance
STAT+: Roche expands its Boston footprint with new research center
STAT News - Data & Analysis